Pattern of use of biologics in psoriasis among Indian dermatologists – A cross sectional survey

Abstract

Background and Aims: Biologics are a relatively new class of highly effective drugs in the management of psoriasis. They act on specific immune processes, achieve rapid and sustained clearance and do not cause target organ damage unlike conventional systemic therapy. It appears that their use in our country is not as widespread as in developed nations despite these benefits ; their prohibitive cost may be a major factor for the limited usage. This survey aimed to find out the extent of use and factors hindering usage of biologics for the management of psoriasis by Indian dermatologists. Methods: It was a cross-sectional questionnaire based study. The questionnaire was designed after a focussed group discussion, followed by validation. The survey was sent in the form of a link to Indian dermatologists. The responses were recorded in excel-sheet and the data was analyzed by SPSS ver 25. Results: Of the 310 participants who took part, 287 completed the survey. Two hundred (70%) were users of biologics, while 87 (30%) had never used them. Cost was the major factor which prevented biologic use. Majority of the respondents used biologics in less than 2 cases per month. Secukinumab was the most common biologic used followed by etanercept. The factors which determined choice of biologics were convenience, cost, previous experience, co-morbid conditions and recommendations by an expert. Limitations: A small sample size was the limitation of the study. Dermatologists who do not use biologics may be under-represented in the study. Conclusions: Biologics are not used optimally by Indian dermatologists for management of psoriasis. The cost, fear of adverse effects, lack of awareness and inadequate felt need are major factors which prevent their regular use.

Infectious Disease Screening prior to Systemic Immunomodulatory Therapy in Hidradenitis Suppurativa: Consensus Guidelines from the Asia-Pacific Hidradenitis Suppurativa Foundation

“…Clinical trials of novel immunomodulatory agents are often the major source of information regarding infectious complications in systemic inflammatory disease. However, monoclonal antibody therapy is increasingly being used on a global scale where unique endemic diseases and complications may arise [99]. Additionally, significant numbers of participants with disease reactivation may not be identified until many years after a medication has been widely used [100].…”

Therapeutic Inertia in the Management of Psoriasis: A Quantitative Survey Among Indian Dermatologists and Patients

“…24 However, biologics are not used optimally by the Indian dermatologists owing to cost, fear of adverse effects, lack of awareness, and a perception of inadequacy. 49 Nonetheless, the global use of biologics in the past decade has significantly changed the treatment algorithm for psoriasis, thereby greatly affecting the treatment choices in a clinical setting. 50 Majority of the patients lack awareness and appreciable knowledge about possibility of attaining substantial improvement or elimination of their most troublesome symptoms.…”